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Abstract
Background: The strong association between aberrant HDAC activity and the occurrence of
cancer has led to the development of a variety of HDAC inhibitors (HDIs), which emerge as
promising new targeted anticancer therapeutics.
Methods: Due to the pivotal role of RelA/p65 in the tumorigenesis of pancreatic neoplasia we
examined the expression of class I HDACs 1, 2 and 3 in a large cohort of human pancreatic
carcinomas and correlated our findings with RelA/p65 expression status. Furthermore, we
investigated the impact of the HDIs SAHA and VPA on RelA/p65 activity in pancreatic cancer cell
culture models.
Results: Class I HDACs were strongly expressed in a subset of pancreatic adenocarcinomas and
high expression was significantly correlated with increased nuclear translocation of RelA/p65 (p =
0.024). The link of HDAC activity and RelA/p65 in this tumor entity was confirmed in vitro, where
RelA/p65 nuclear translocation as well as RelA/p65 DNA binding activity could be markedly
diminished by HDI treatment.
Conclusion: The RelA/p65 inhibitory effects of SAHA and VPA in vitro and the close relationship
of class I HDACs and RelA/p65 in vivo suggest that treatment with HDIs could serve as a promising
approach to suppress NF-κB activity which in turn may lead to enhanced apoptosis and
chemosensitization of pancreatic cancers.
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Background
Posttranslational modifications such as acetylation and
deacetylation of histone proteins play an important role
in chromatin remodelling and transcriptional regulation
[1]. Two groups of corresponding enzymes, histone
deacetylases (HDACs) and histone acetyl-transferases
(HATs) act in concert to maintain the balance between
condensed and relaxed chromatin by catalyzing the
removing or adding of acetyl groups to specific lysine-rich
amino terminal histone residues. Chromatin condensa-
tion due to high HDAC activity leads to transcriptional
silencing of a subset of genes involved in differentiation
and inhibition of proliferation, apoptosis and metastasis
[2]. Furthermore, HDACs are able to directly deacetylate
tumor relevant non-histone proteins such as p53, GATA-
1, β-catenin and NF-κB (RelA/p65) [3], which may alter
their activity, subcellular localization and interaction part-
ners.
In humans, four structurally diverse classes of HDACs
comprising 18 isoforms have been identified so far with
class I HDACs 1, 2 and 3 being the best characterized and
most abundantly expressed isoforms in tumor tissues [4].
Due to the fact that aberrant HDAC activity has been asso-
ciated with the occurrence of different types of cancers
[5,6], a variety of clinically applicable HDAC inhibitors
(HDIs) have been developed and tested during the past
few decades [3,7-10].
HDIs have shown to suppress tumor growth and to
induce differentiation and apoptosis in various studies
both, in vitro and in vivo [2,11]. Some of them including
suberoylanilide hydroxamic acid (SAHA) and valproic
acid (VPA) are in late-phase clinical trials for the treatment
of solid tumors and show promising effects with low tox-
icity [3]. Recently SAHA was approved by the Food and
Drug Administration for the clinical use in patients with
cutaneous T-cell lymphoma [12].
Pancreatic adenocarcinoma is the fourth leading cause of
cancer death in the United States. Due to the high chem-
oresistance and the fact that only 5-28% of pancreatic car-
cinomas are surgically resectable at the time of diagnosis
the possibilities of curative therapy are highly restricted.
Thus, 5-year survival rate is lower than 5% [13]. New strat-
egies for the treatment of pancreatic carcinoma, particu-
larly with regard to the avoiding of chemoresistance are
urgently needed [14].
Reduced sensitivity to chemotherapeutic agents is often
associated with a constitutive active Rel/NF-κB pathway
[15,16]. The Rel/NF-κB family consists of various mem-
bers of transcription factors, p50/p105 (NF-κB1), p52/
p100 (NF-κB2), c-Rel, RelB and p65 (RelA), which are
responsible for the regulation of immune and inflamma-
tion related genes such as cytokines, cytokine-receptors
and cell adhesion molecules [17]. Overexpression and/or
dysregulation of certain regulatory proteins of the NF-κB
pathway, e.g. the heterodimer p65/p50, have been linked
to higher tumor grade and poor prognosis in consequence
of increased cell proliferation, angiogenesis and metasta-
sis [18,19].
NF-κB activation can be regulated at several levels. In rest-
ing cells, inactivated NF-κB is sequestered in the cyto-
plasm by the inhibitory factor IκBα. In response to
specific pro-inflammatory signals such as tumor necrosis
factor-α (TNF-α) and interleukin-1β (IL-1β), IκBα
becomes phosphorylated, ubiquitinylated and subse-
quently degradated allowing a rapid nuclear translocation
and thereby activation of NF-κB [17]. Apart from translo-
cation based activation, NF-κB can be regulated by prote-
olytic procession or posttranslational modifications like
HDAC mediated acetylation or deacetylation, suggesting a
potential RelA/p65 inhibitory effect of HDIs like SAHA
and VPA [20].
In this study we, for the first time, investigated the expres-
sion of class I HDACs in a large cohort of human pancre-
atic carcinomas. Due to the pivotal role of RelA/p65 in the
tumorigenesis of pancreatic carcinoma we correlated our
findings with RelA/p65 expression status. Based on the
fact that RelA/p65 is a putative target of HDIs, we addi-
tionally tested the effects of the two well known HDIs
SAHA and VPA on RelA/p65 activity in vitro.
Methods
Study Population
Tissue samples from 81 patients who underwent partial
pancreaticoduodenectomy for primary pancreatic ductal
adenocarcinoma at the Charité University Hospital
between 1991 and 2000 were used in this study. The study
has been approved by the Charité University Ethics Com-
mittee under the title "Retrospektive Untersuchung von
Gewebeproben mittels immunhistochemischer Färbung
und molekularbiologischer Methoden" ("Retrospective
analysis of tissue samples by immunohistochemistry and molec-
ular biological techniques"; EA1/06/2004) at the 20th of Sep-
tember 2004.
Median age of patients with pancreatic cancer was 66
years (range 39-80 years). Follow-up data regarding over-
all survival were available for all patients. Within the fol-
low up time, 64 patients (79%) died after a median follow
up time of 11.7 months. Median follow-up time of
patients still alive at the endpoint of analysis was 44.0
months. Cases were staged according to "TNM Classifica-
tion of Malignant Tumours. 6th edition" (Sobin LH, Wit-
tekind C.; 2002) and cases were graded as recommendedBMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
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by the WHO [21]. Distribution of clinico-pathological
factors in the study cohort is given in Additional file 1.
Immunohistochemical staining and histopathological 
examination
RelA/p65 expression patterns had been determined in 78
of the 81 cases in a previous study [18]. For immunohis-
tochemical detection of HDAC isoforms on tissue sam-
ples, prediluted polyclonal rabbit IgG antibody directed
against HDAC1 (1:11, Abcam, Cambridge, UK), mono-
clonal mouse IgG antibody directed against HDAC2
(1:5000, Abcam) and monoclonal mouse IgG antibody
directed against HDAC3 (1:500, BD Biosciences) were
used on 5 μm paraffin sections. Antibody specificity had
already been ascertained in a previous study [22]. Immu-
nohistochemistry was done as previously described [22].
Nuclear staining of HDAC isoforms was scored by apply-
ing a semiquantitative immunoreactivity scoring (IRS)
system, as previously described [22]. Briefly, intensity of
staining as well as percentage of cells stained was evalu-
ated separately. The IRS for each individual case ranging
from 0 to 12 was calculated by multiplication of the inten-
sity and frequency scores. Cases exhibiting an IRS from 0-
6 were combined in one group (HDAC negative), cases
with an IRS of more than 6 were combined in a HDAC
positive group. In addition, the patients were grouped
according to their overall class I HDAC expression pattern
(all three isoforms negative versus one or two isoforms
positive versus all three isoforms positive). Staining of tis-
sue slides was evaluated by an experienced pathologist
(WW) who was blinded towards patient characteristics
and outcome.
Statistical evaluation
Statistical analyses were carried out with SPSS 15.0 and
GraphPad Prism 4.0. The significance of correlations
between HDAC isoform staining patterns and clinico-
pathological data was assessed by Fisher's exact test and χ2
test for trends. The correlation of the expression of single
HDAC isoforms with each other as well as with cytoplas-
mic and nuclear RelA/p65 was determined by Spearman
rank order correlation (raw scores) and χ2 test for trends
test (grouped).
Survivor curves were estimated by the Kaplan-Meier
method. Differences in survival were assessed by a log
rank test. Statistical analysis of transcription factor assays
was done by columnar t-test. P-values < 0.05 were consid-
ered statistical significant.
Cell lines
The human epithelial pancreatic cell line PANC-1 was
obtained from ATCC and cultured in Dulbecco's modified
Eagle's medium supplemented with 10% heat inactivated
fetal bovine serum and 1 mM glutamine.
RNA interference
Predesigned RelA/p65 siRNA duplexes were purchased
from Qiagen (Hilden, Germany; target sequence: AAG
CAT TAA CTT CTC TGG AAA, sense: r(GCA UUA ACU
UCU CUG GAA A)dTdT; antisense: r(UUU CCA GAG
AAG UUA AUG C)dTdT. A nonsilencing siRNA (Control
siRNA, Qiagen)) was used as negative control. Cells were
transfected with 60 pmol siRNA per well using TransMes-
senger transfection reagent according to the manufac-
turer's instructions. Efficacy of transfection was checked
after 72 h by immunoblotting.
Immunoblotting
Total cell lysates from 0,6 × 105 cells/ml were prepared by
lysing cells in 30 μl p38 buffer (62,5 mM Tris HCl, pH 6,8;
2% SDS; 10% glycerol; 50 mM DTT in H2O) for 10 min
on ice and centrifugation for 15 min at 14 000 rpm.
Supernatant was used to ascertain protein concentration
using a BCA Protein Assay Kit (PIERCE Biotechnology,
Rockford, IL, USA). Protein samples (100 μg) were dena-
turated at 95°C and subsequently separated on a 12%
SDS-PAGE gel. After transfer to nitrocellulose membrane
and blocking with I-Block (Tropix, Bedford, MA, USA) for
20 min the samples were probed with Acetyl-H3-antibody
(Upstate, Billerica, MA, USA; 1:1000), IκBα antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200),
Phospho-IκBα antibody (Epitomics, Burlingame, CA,
USA; 1:7000), RelA/p65 antibody (Santa Cruz; 1:250) or
antibody against β-actin (Chemicon, Billerica, MA, USA;
1:2500) over night and washed three times with washing
buffer (0,1% tween-20 in PBS). Incubation with second-
ary antibody (Tropix, AP conjugated goat-anti mouse anti-
body, 1:5000; AP conjugated goat-anti rabbit antibody,
1:5000; 45 min at room temperature) was followed by
another wash and subsequent visualisation using CDPstar
substrate (Tropix).
Immunofluorescence
For immunofluorescence, cells were seeded into 4-well-
labTEK chamber slides (NUNC, Roskilde, Denmark) at a
density of 0,4 × 105 cells/ml, grown over night and then
treated with given concentrations of SAHA (QBiogene,
Heidelberg, Germany) or VPA (Sigma-Aldrich, Steinheim,
Germany) for 72 h. Stimulation was done by adding 2 μl/
ml IL-1β one hour before fixation. Cells were fixed with
ice-cold 70% ethanol for 20 min at -20°C and subse-
quently blocked with serum containing buffer (10% BSA,
1% NGS in PBS) for 30 min. To remove goat serum,
chamber slides were washed three times with PBS and
probed with primary antibody against RelA/p65 (Santa
Cruz Biotechnology, 1:50). Following another wash, cells
were incubated with Cy3-conjugated anti-mouse anti-
body (Jackson ImmunoResearch, West Grove, PA, USA;
1:200) and 2,5 μl DAPI for 30 min at room temperatureBMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
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and finally visualized by confocal fluorescence micros-
copy (Leica, Solms, Germany).
NF-κB RelA/p65 transcription factor assay
For measurement of RelA/p65 activity an EZ-Detect Tran-
scription Factor Kit (PIERCE Biotechnology) was used,
according to the manufacturer's instructions.
In brief, 20 μg of total protein extract was incubated on a
streptavidin-coated 96-well plate with bound NF-κB bioti-
nylated-consensus sequence and detected by specific
RelA/p65 antibody and secondary HRP conjugated anti-
body. After adding a chemiluminescent substrate, binding
capability of RelA/p65 was quantified at a luminometer
(Labsytems Luminoscan, Helsinki, Finland). To ensure
signal specificity, NF-κB Competitor Duplex (PIERCE Bio-
technology) as well as specific RelA/p65 siRNA were used
as positive/negative controls.
Results
Expression patterns of class I HDAC isoforms and nuclear 
RelA/p65 in pancreatic carcinoma and correlation with 
clinico-pathological data
To test the impact of class I HDAC expression in human
pancreatic carcinoma in vivo and to elucidate possible
interactions of HDACs and RelA/p65 we evaluated the
expression of class I HDACs 1, 2 and 3 by immunohisto-
chemistry and correlated expression data with clinico-
pathological features, patient prognosis as well as RelA/
p65 expression and nuclear translocation, which has been
determined in a previous study in an overlapping cohort
[18].
Normal acinar cells, normal ductal cells as well as stromal
fibroblasts showed occasional weak to moderate positiv-
ity for all three HDAC isoforms. Pancreatic adenocarci-
noma displayed strong nuclear immunoreactivity for
HDAC1 (32%), HDAC2 (63%), HDAC3 (79%) and RelA/
p65 (45%) in a considerable number of cases (Figure 1).
Some expression was also evident in desmoplastic stroma
cells and inflammatory cells. Raw expression scores of
HDAC1, HDAC2 and HDAC3 correlated significantly
with each other (Table 1), suggesting a shared regulation
of these isoforms. High HDAC2 expression was signifi-
cantly associated with poor tumor differentiation (p =
0.039). No other correlations of HDAC isoforms with
clinico-pathological parameters were found (see Addi-
tional file 1). Interestingly, we found a positive correla-
tion between RelA/p65 expression and HDAC isoform
expression. Categorized grouped HDAC scores signifi-
cantly correlated with the presence of nuclear RelA/p65 (p
= 0.028, data not shown). To further elucidate the
strength of the relationship, raw expression scores were
compared. Here we found that both cytoplasmic as well as
nuclear RelA/p65 positivity was significantly linked with
the expression of specific HDAC isoforms, the strength of
those correlations were weak to moderate. When the
grouped HDAC scores were correlated with RelA/p65
expression, only the relation to nuclear RelA/p65 expres-
sion was significant (p = 0.024). The correlation with cyto-
plasmic RelA/p65 expression showed borderline
significance (p = 0.059, Table 1). This supports a func-
tional relationship between HDAC activity and RelA/p65
expression and nuclear translocation (indicating activa-
tion). In contrast to nuclear RelA/p65 expression [18]
Table 1: Correlation of HDAC1, 2 and 3 expression scores (IRS) with cytoplasmic and nuclear RelA/p65 positivity (IRS).
Nuclear RelA/p65
IRS
HDAC1
IRS
HDAC2 IRS HDAC3 IRS HDAC grouped IRS
Cytoplasmic n = 78 n = 78 n = 78 n = 78 n = 78
RelA/p65 r = 0.640 r = 0.191 r = 0.246 r = 0.105 r = 0.215
IRS p < 0.001 p = 0.094 p = 0.030 p = 0.358 p = 0.059
Nuclear n = 78 n = 78 n = 329 n = 78
RelA/p65 r = 0.213 r = 0.138 r = 0.132 r = 0.255
IRS p = 0.063 p = 0.229 p = 0.249 p = 0.024
n = 81 n = 81 n = 81
HDAC1 IRS r = 0.279 r = 0.282 r = 0.670
p = 0.012 p = 0.011 p < 0.001
n = 81 n = 81
HDAC2 IRS r = 0.363 r = 0.681
p = 0.001 p = 0.006
n = 81
HDAC3 IRS r = 0.572
p < 0.001BMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
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HDAC1, HDAC2 and HDAC3 as well as RelA/p65 expression in pancreatic carcinomas Figure 1
HDAC1, HDAC2 and HDAC3 as well as RelA/p65 expression in pancreatic carcinomas. (A/C/E/G) Serial sections 
of a pancreatic ductal adenocarcinoma infiltrating a lymph node. Note strong expression of HDAC1 (A), HDAC2 (C), 
HDAC3 (E) and nuclear positivity for RelA/p65 (G). Magnification ×100. (B/D/F/H) Serial sections of a ductal pancreatic ade-
nocarcinoma showing nuclear positivity for HDAC1 (B), HDAC2 (D) and HDAC3 (F). Strong expression of the three iso-
forms is accompanied by strong nuclear translocation of RelA/p65 (H). Weak cytoplasmic RelA/p65 positivity can be seen in 
this case, as well. Magnification ×400.BMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
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expression of HDAC isoforms 1, 2 and 3 did not have
prognostic impact in univariate survival analyses (see
Additional file 2 and Additional file 3). For the conven-
tional prognostic parameters tumor grade and nodal sta-
tus a significant correlation with overall survival could be
ascertained in our cohort (grade: p = 0.01; nodal status: p
= 0.05) (see Additional file 2).
Inhibition of RelA/p65 activity by treatment with SAHA 
and VPA
Based on the association of class I HDAC expression and
nuclear RelA/p65 translocation in pancreatic adenocarci-
noma in vivo and the fact that RelA/p65 is a putative target
of HDIs we wanted to know if this link could be function-
ally confirmed for pancreatic cancer in vitro.
First, to show that inhibition of nuclear translocation is in
fact linked to a decreased activity of RelA/p65, we per-
formed a RelA/p65 specific transcription factor assay
which measures the binding activity of the protein. Since
the amount of activated RelA/p65 was comparatively low
under cytokine absence, RelA/p65 activity was enhanced
by stimulation with IL-1β. Stimulation of cells with IL-1β
led to an increase of RelA/p65 activity of ~40% in PANC-
1 cells. As shown in figure 2A, wild type competitor
duplex, but not mutant NF-κB competitor duplex was
able to prevent RelA/p65 from binding to the attached
consensus sequence. RelA/p65 specific siRNA knock-
down, whose efficacy was checked by immunoblotting,
reduced RelA/p65 binding activity by ~50% (Figure 2A).
As shown in figure 2B, treatment with SAHA and to a
lesser degree treatment with VPA resulted in a time-
dependent reduction of RelA/p65 activity of up to 50%. In
PANC-1 cells, 24 h of VPA treatment decreased RelA/p65
activity by approximately 25%, however, this effect could
not be intensified by extension of treatment periods and
was not statistically significant. Although lesser effects
were also seen for SAHA at shorter time points, a strong
and significant RelA/p65 inhibitory effect was only seen
after 72 h. As shown in figure 2A and 2B, treatment of cells
with 8 μM SAHA for 72 hours was able to diminish RelA/
p65 binding activity to the same degree as specific RelA/
p65 siRNA knockdown did (~50%). In addition, we
found an influence of HDIs SAHA and VPA on the subcel-
lular localization of RelA/p65 by exploratory immunoflu-
orescence analysis. The results of RelA/p65 specific
immunofluorescence are shown in figure 2. In untreated
(2C) PANC-1 cells we observed a strong signal of RelA/
p65 predominantly in the nucleus. Both SAHA (2D) and,
to a lesser degree VPA (2E), led to a cytoplasmic retention
of the protein after 72 h in stimulated cells.
Both, SAHA and VPA did not affect protein levels of IκBα.
Interestingly, phosphorylation of IκBα was notably inhib-
ited by both substances after 72 h of treatment. In con-
trast, enhanced acetylation of histone H3 could be already
observed after 12 h of HDI exposure (Figure 3).
Discussion
Our study, to our knowledge for the first time, displays a
statistically significant in vivo correlation between class I
HDAC isoform expression in pancreatic carcinoma and
the presence of nuclear RelA/p65, a protein known to be
a key regulator in pancreatic carcinogenesis. Furthermore,
we could demonstrate that HDAC inhibitors are effective
in inhibiting nuclear activation and binding capability of
RelA/p65 in pancreatic cancer cells.
Although there is strong evidence that aberrant HDAC
activity can contribute to the development of cancer,
reports on isoform specific expression patterns of HDACs
in tumor tissue are sparse [23,24]. In line with previous
studies of our group, which focussed on HDAC expression
in malignancies of other organs like prostate and colon
[25,26], pancreatic tumor tissue displayed a high degree
of class I HDAC expression with HDAC3 being the most
abundantly expressed isoform. Additionally, our in vivo
data indicate that a distinct HDAC "high" subgroup is
likely to show strong RelA/p65 nuclear translocation/
activity, which is of particular interest in pancreatic carci-
noma, since activation of the NF-κB pathway is associated
with pancreatic cancer development and progression and
is an adverse prognosticator for this entity [18]. However,
unlike RelA/p65, high class I HDAC expression did not
attain statistical significance for overall survival in pancre-
atic carcinoma in our study, which might be explained by
the fact that although we see a correlation between those
parameters in our in vivo data the correlation is not
extremely strong. This suggests that RelA/p65 is only
partly regulated/activated by strong HDAC expression.
Furthermore, nuclear RelA/p65 as well as cytoplasmic
(borderline significant) RelA/p65 positivity was linked to
increased HDAC expression when comparing the distri-
butions of raw expression data, which suggests at least in
part a transcriptional regulation and not only a post tran-
scriptional modification of RelA/p65 activity by HDACs.
Our survival results are somewhat in contrast to the results
reported by Miyake et al. [27], who found a prognostic
impact of HDAC1 expression in a moderately large cohort
(39 cases) of pancreatic cancers. We cannot exclude that in
certain cohorts of pancreatic cancer (e.g. Japanese
patients) such a correlation might exist, however, in our
Western European cohort which is twice as large (82
cases) as Miyake's cohort, we were not able to confirm
these findings and therefore have to conclude that this
observed correlation is not universially applicable. Since
cut-off values for defining HDAC1 positive/negative cases
in Miyake's and our study were different, we repeated our
analysis with the cut-offs used by Miyake. However, thisBMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
Page 7 of 10
(page number not for citation purposes)
Effects of HDIs on DNA binding activity and nuclear translocation of RelA/p65 in stimulated PANC-1 cells Figure 2
Effects of HDIs on DNA binding activity and nuclear translocation of RelA/p65 in stimulated PANC-1 cells. (A) 
Signal specificity of the transcription factor assay was ensured by the use of Wild Type NF-κB Competitor Duplex (WT) (nor-
malized to Mutant NF-κB Competitor Duplex (Mut.)) as well as by specific RelA/p65 siRNA treatment (72 h, normalized to 
Control siRNA) (*: p = 0.05; columnar t-test); Western Blot showing specific knockdown of RelA/p65 protein expression by 
RelA/p65 siRNA treatment in comparison with control siRNA and untreated cells. (B) RelA/p65 binding activity as measured 
in a transcription factor assay was markedly diminished in response to 72 h of HDI treatment (*: p = 0.05; columnar t-test, IL-
1β stimulated PANC-1 cells). (C-E) RelA/p65 specific immunofluorescence. RelA/p65 specific immunofluorescence showed a 
strong nuclear RelA/p65 staining in response to IL-1β stimulation (C). IL-1β induced nuclear translocation of RelA/p65 was 
markedly diminished by (D) SAHA treatment (8 μM) and (E) VPA treatment (8 mM) (72 h).BMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
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did not result in a significant survival difference, either (p
> 0.05, data not shown).
The finding that HDAC activity is linked to the activity of
RelA/p65 in pancreatic carcinoma in vivo could be also
confirmed in an in vitro cell culture model, where treat-
ment of cells with the HDI SAHA led to a markedly
decrease in nuclear translocation and binding activity of
RelA/p65. This is in line with previous studies which
reported RelA/p65 inhibitory effects of HDIs like Trichos-
tatin A and SAHA in other cell culture systems [28,29]. In
contrast, Chen et. al. reported an increase in nuclear trans-
location and activation of RelA/p65 in response to HDI
treatment [30] which suggests that the impact of
enhanced RelA/p65 acetylation is dependent on the
tumor entity and the HDI used.
The underlying mechanisms and the consequences of
RelA/p65 acetylation and deacetylation can't be clarified
completely within the scope of this translational work.
This should be done in future functional studies. One pos-
sible mechanism by which RelA/p65 could be inhibited
by HDIs might be the loss of IκBα phosphorylation,
which we observe in our in vitro experiments and which
should lead to an enhanced IκBα accumulation and
sequestering of RelA/p65 in the cytoplasm.
Even though treatment with VPA resulted in a partial
removal of nuclear translocated RelA/p65 into the cyto-
plasm in our experiments as well, VPA was less effective in
inhibiting DNA binding activity of the transcription factor
than SAHA. The different effectiveness of the two HDIs in
deactivating RelA/p65 might be explained by the fact that
SAHA is known to act on various HDAC isoforms whereas
VPA preferentially inhibits class I HDACs [3,31].
Strong antineoplastic effects of SAHA like growth inhibi-
tion, induction of apoptosis and cell cycle arrest have
been demonstrated in various studies [2,3,7]. Our in vitro
data on inhibition of RelA/p65 activity indicate that these
effects could be partly based on an alteration of the NF-κB
signalling pathway. This finding could be of special inter-
est for the development of new treatment strategies for
pancreatic carcinoma, since chronic inflammation due to
elevated activities of mediators like NF-κB are conductive
to pancreatic carcinogenesis [32]. Furthermore, conven-
tional chemotherapeutics like gemcitabine or paclitaxel
are often associated with high resistance rates in pancre-
atic neoplasms, which is partly due to a constitutively acti-
vated RelA/NF-κB pathway [15,33]. A combinational
treatment with HDIs which are able to inhibit RelA/p65
activity might be of use to overcome such resistances.
Conclusion
In conclusion, we demonstrated that class I HDACs are
overexpressed in pancreatic cancer and that high class I
HDAC expression is significantly correlated to nuclear
translocation of the transcription factor RelA/p65 in pan-
creatic adenocarcinoma. The close relationship of class I
HDACs and RelA/p65 was confirmed in vitro, where
nuclear translocation and binding activity of RelA/p65
could be markedly diminished by treatment of pancreatic
cancer cells with HDAC inhibitors.
Our data support the assumption that treatment with
HDAC inhibitors, either as single agents or in combina-
tion with other chemotherapeutics, could serve as a
potential approach in the targeted therapy of pancreatic
carcinoma.
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Effects of SAHA and VPA on IκBα protein level and histone  acetylation in PANC-1 Figure 3
Effects of SAHA and VPA on IκBα protein level and 
histone acetylation in PANC-1. Western Blot showing 
acetylated histone H3 as well as protein levels of IκBα, p-
IκBα and β-Actin in response to SAHA (8 μM) and VPA (8 
mM) treatment. HDI treatment led to an increase of histone 
H3 acetylation and markedly diminished phosphorylation of 
IκBα.BMC Cancer 2009, 9:395 http://www.biomedcentral.com/1471-2407/9/395
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